Logo of Cann (ASX:CAN)Latest Cann (ASX:CAN) News

Page 1
Page 1 of 4

Cann Group targets export growth as Mildura reset nears cash flow test

Cann Group says its balance-sheet repair and cost cuts have created room for growth, with September-quarter revenue and exports jumping. But the medicinal cannabis producer remains loss-making on a normalised basis and is now under pressure to turn improving sales into consistently positive cash flow.
Ada Torres
18 Nov 2026

Healthcare Wrap - Week 44 (26 Oct -> 30 Oct) 2026

Healthcare shares split between clinical progress and cash pressure this week. Mesoblast rose on stronger Ryoncil sales, while several small biotechnology companies fell as investors weighed funding needs and delayed milestones.
Logan Eniac
31 Oct 2026

Cann Group lifts exports and revenue, but cash runway remains under one quarter

Cann Group’s September quarter delivered a sharp increase in revenue and exports as its Mildura GMP facility gained traction in Europe. But with just $49,000 in cash, $626,000 of undrawn debt capacity and an estimated 0.9 quarters of funding, the recovery still depends on collections and further financing.
Ada Torres
30 Oct 2026

Cann Group Turns Debt Crisis Into Profit, But Cash Earnings Remain Elusive

Cann Group’s FY2026 profit was transformed by a one-off A$55.7 million debt-forgiveness gain, while a leaner cost base and new export sales offered more durable progress. The company remains loss-making on a normalised basis and dependent on lender waivers and a future refinancing.
Victor Sage
30 Sept 2026

Healthcare Wrap - Week 31 (27 July -> 31 July) 2026

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.
Logan Eniac
1 Aug 2026

Cann Group Advances Cash Flow and Export Growth Amid Leadership Shift

Cann Group reported its second-ever quarterly operating cash inflow of $0.24 million in Q4 FY2026, edging closer to cash flow break-even. The company expanded exports to the UK and Germany, launched new products, and completed a leadership transition while redeeming convertible notes and securing additional credit.
Ada Torres
30 July 2026

Healthcare Wrap - Week 27 (29 June -> 3 July) 2026

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.
Logan Eniac
4 July 2026

Cann Group Expands Private Credit Facility by $2 Million to Redeem Convertible Notes

Cann Group has boosted its private credit loan facility by $2 million to facilitate the early redemption of convertible notes, maintaining its debt restructuring momentum.
Ada Torres
3 July 2026

Cann Group Redeems Convertible Notes Early at Face Value, Waiving Premium

Cann Group Limited has agreed to fully redeem its outstanding convertible notes with Obsidian Global GP, LLC at 100% of face value, foregoing the usual early redemption premium. This move concludes the convertible securities facility established earlier in the year.
Ada Torres
30 June 2026

Healthcare Wrap - Week 19 (4 May -> 8 May) 2026

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.
Logan Eniac
9 May 2026

Cann Group CEO Pilcher Resigns After Major Debt Cut; Chairman Steps Up Temporarily

Cann Group’s CEO Jenni Pilcher steps down after leading a dramatic debt reduction and cost overhaul. Chairman Mike Ryan takes interim charge as the company hunts for a new CEO.
Ada Torres
5 May 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026